Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Phasellus varius turpis
$56.00Add to cartPhasellus varius turpis consequat enim tincidunt, id aliquam orci hendrerit. Curabitur quis accumsan nisl, in condimentum magna. Fusce nec diam et dolor ornare rhoncus nec ut mauris. In eleifend mi in felis dictum fermentum. Morbi vel arcu sit amet dolor venenatis bibendum in eu dui.
-
Quick View
Mauris elit magna, aliquet
$50.00Add to cartFusce sagittis tellus eget ante gravida euismod. Mauris interdum, neque eu hendrerit aliquet, diam nisi fringilla nisi, at convallis ante velit sed erat. Vestibulum mollis lorem ut molestie pharetra. Sed pretium quam lacinia, placerat urna a, tincidunt massa. Mauris elit magna, aliquet blandit mauris eu
-
Quick View
The Benefits of Roof Insulation: Is it a Wise Investment?
Read moreRoof insulation is a topic that often goes unnoticed, yet it plays a crucial role in maintaining a comfortable and energy-efficient home. Many homeowners wonder whether insulating their roof is a good idea. In this article, we will delve into the benefits of roof insulation, exploring its impact on energy efficiency, cost savings, and overall …
The Benefits of Roof Insulation: Is it a Wise Investment?Read More
-
Quick View
Nulla feugiat felis tempor sem
$61.00Add to carteget ullamcorper leo auctor. Donec at interdum nibh, in blandit massa. Nam pulvinar mollis quam, vel fringilla mi interdum elementum. Donec ullamcorper turpis et libero sagittis vestibulum. Donec enim nisl, rhoncus vitae magna eu, convallis tempus tortor. Integer et facilisis metus.
Reviews
There are no reviews yet.